Home › NDC Lookup › RxCUI directory › RxCUI 1594658

1.2 ML alemtuzumab 10 MG/ML Injection — RxCUI 1594658

RxNorm drug concept · Semantic clinical drug
RxCUI 1594658 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1594658
Official name1.2 ML alemtuzumab 10 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asalemtuzumab 12 MG per 1.2 ML Injection; alemtuzumab 12 MG in 1.2 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alemtuzumab Injection (Chronic Lymphocytic Leukemia): what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Alemtuzumab is generally reserved for people whose MS hasn't responded well enough to at least two other medications. It's a more aggressive treatment that can make a real differen...
  • Why is my doctor recommending this medication when there are other MS treatments out there?
  • Each infusion takes about 4 hours, and you'll need to stay for at least 2 more hours of monitoring afterward. Before the infusion, you'll receive a corticosteroid medication to hel...
  • What should I expect on the days I get the infusion?
📖 Read our full Alemtuzumab Injection (Chronic Lymphocytic Leukemia) guide →

🕸️ Concept Web — How 1.2 ML alemtuzumab 10 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 1.2 ML alemtuzumab 10 MG/ML Injection RxCUI 1594658

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Alemtuzumab 117055
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lemtrada 1594659
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Alemtuzumab Injection 1656629
    • Alemtuzumab Injectable Product 1164265
    • Alemtuzumab Injection [Lemtrada] 1656637
    • Lemtrada Injectable Product 1594662
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Alemtuzumab 10 MG/ML SCDC · 1594657
  • Alemtuzumab Injection SCDF · 1656629
  • Alemtuzumab Injectable Product SCDG · 1164265

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1594658 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
58468-0200-01 1 VIAL, SINGLE-USE in 1 CARTON (58468-0200-1) / 1.2 mL in 1... LEMTRADA Genzyme Corporation 2014-11-18
Observed labelers: Genzyme Corporation (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J0202 Injection, alemtuzumab 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.